[Federal Register Volume 75, Number 108 (Monday, June 7, 2010)]
[Notices]
[Pages 32185-32186]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-13597]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of

[[Page 32186]]

federally-funded research and development. Foreign patent applications 
are filed on selected inventions to extend market coverage for 
companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Software System for Analysis of Extremely Large Experimental Dataset 
and Multidimensional Drug Discovery

    Description of Invention: This invention is a computer software 
suite that will enable its user to investigate extremely large 
experimental datasets in a simple yet multidimensional manner. The 
software, Omnimorph, allows multidimensional investigation of any form 
of data including experimental datasets in biomedical science using 
either gene arrays or proteomics. Omnimorph allows the user to look for 
extremely subtle correlated differences between experimental datasets 
which will allow the investigator to discover far more drug- or 
disease-specific factors than other analytical methods currently used. 
The software of present invention has been employed in the targeted 
discovery of G protein-independent receptor-based pharmacotherapeutics. 
These discoveries represent an entirely new GPCR-based G protein-
independent pharmacopeia. Therefore, the Omnimorph is not only newly 
developed software, but the Omnimorph suite can also be used as a 
simple and unbiased tool to detect novel and unexpected modes of GPCR-
based drug actions. This could potentially alter the way drugs are 
developed and screened in the future.
    Applications:
     Development and screen for pharmaceutical drugs.
     Biomedical research.
    Development Status:
     The invention has been fully developed.
     The software will be readily available if so requested.
    Inventors: Stuart R. Maudsley et al. (NIA).
    Patent Status: HHS Reference No. E-143-2010/0--Research Tool. 
Patent protection is not being pursued for this technology.
    Licensing Status: Available for licensing.
    Licensing Contacts: Uri Reichman, PhD, MBA; 301-435-4616; 
[email protected]; or Michael Shmilovich, Esq.; 301-435-5019; 
[email protected].
    Collaborative Research Opportunity: The National Institute on 
Aging, Laboratory of Neurosciences-Receptor Pharmacology Unit, is 
seeking statements of capability or interest from parties interested in 
collaborative research to further develop, evaluate, or commercialize 
this technology. Please contact John Hewes, PhD at 301-435-3131 or 
[email protected] for more information.

Sound Attenuation Canopy for Reducing Noise Transmitted Through 
Suspended Ceilings

    Description of Invention: Available for licensing and commercial 
implementation in commercial facilities design and construction are 
intellectual property rights covering a sound attenuation canopy for 
reducing noise transmitted through suspended ceiling systems commonly 
used in most office buildings. The canopy is designed to absorb sound 
energy and effectively reduce the direct path of sound travelling 
within open plenum suspended ceilings like those used in most office 
building environments. The canopy can also act as an umbrella to shield 
loose debris and dust which may be located in the plenum and 
potentially fall when ceiling suspended return-air grilles are moved or 
accessed. The canopy has an added benefit of reducing heating or 
cooling loss which may naturally ventilate through the return air 
plenum grille from a conditioned office space below. Also, the canopy 
controls leakage of heating and cooling, reducing loads on the central 
building systems thereby lessening energy costs and extending the life-
cycle of the building's physical plant.
    The canopy does not impede natural air flow for ventilating the 
plenum cavity but deters the spread of smoke or fire between the plenum 
and the office space below. The canopy can also act as a secondary air 
balancer or K Factor balancer to equate supply and return air to 
control room temperature. The canopy is pliable and therefore allows 
for ease of adjustment within varying plenum conditions as well as 
readily installed in ceiling plenums.
    Applications:
     Building design and construction.
     Sound attenuation.
     Energy load reduction.
    Inventors: Judit A. Quasney, Franklin Koh, John P. Jenkins, Robert 
M. Alexander, Daniel P. O'Brien (NIAID).
    Patent Status: U.S. Patent Application No. 12/764,872 filed 21 Apr 
2010 (HHS Reference No. E-102-2010/0-US-01)
    Licensing Status: Available for licensing.
    Licensing Contact: Michael A. Shmilovich, Esq.; 301-435-5019; 
[email protected].

    Dated: June 1, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-13597 Filed 6-4-10; 8:45 am]
BILLING CODE 4140-01-P